前列地尔联合肾康注射液对慢性肾炎患者尿蛋白、肾功能及血清炎性因子水平的影响  

Effect of Alprostadil combined with Shenkang injection on urine protein,renal function and serum inflammatory in patients with chronic nephritis

作　　者：王琛[1] 顾志峰[2] 王朔[3] 沈良兰[1] 张芬[1] 

机构地区：[1]南通大学第二附属医院肾内科,江苏南通226001 [2]南通大学附属医院风湿免疫科,江苏南通226021 [3]南通大学第二附属医院检验科,江苏南通226001

出　　处：《海南医学院学报》2016年第19期2276-2279,共4页Journal of Hainan Medical University

基　　金：江苏省卫生厅科研项目(P201399)~~

摘　　要：目的:探讨前列地尔联合肾康注射液对慢性肾炎患者尿蛋白、肾功能及血清炎性因子水平的影响。方法:选择2013年5月~2016年5月在我院确诊的96例慢性肾炎患者,随机分为对照组和联合组,各48例。对照组单纯给予肾康注射液治疗,联合组给予前列地尔注射液联合肾康注射液治疗,两组均给予治疗12d。检测并比较两组治疗前后24h尿蛋白定量(24hUpro)、尿β2-微球蛋白(Uβ2-MG)、血清肌酐(SCr)、尿素氮(BUN)、尿白蛋白排泄率(UAER)、超敏-C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、白细胞介素8(IL-8)及白细胞介素18(IL-18)水平。结果:治疗前,两组24hUpro、Uβ2-MG、SCr、BUN及UAER比较差异无统计学意义(P>0.05);治疗后,两组24hUpro、Uβ2-MG、SCr、BUN及UAER均明显低于治疗前,同时联合组以上各指标水平均明显低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组血清hs-CRP、TNF-α、IL-6、IL-8及IL-18等炎性因子水平比较差异无统计学意义(P>0.05);治疗后,两组以上各血清炎性因子水平均明显低于治疗前,同时实验组以上各血清炎性因子水平均明显低于对照组,差异具有统计学意义(P<0.05)。结论:前列地尔联合肾康注射液治疗慢性肾炎,更能够明显减低尿蛋白、血清炎性因子水平,对肾脏有较好的保护作用,值得在临床上推广应用。Objective： To study the effect of alprostadil combined with shenkang injection on urine protein, renal func- tion and serum inflammatory in patients with chronic nephritis. Methods.. A total of 96 patients with chronic nephritis in our hospital from May 2013 to May 2016 were enrolled in this study. The subjects were divided into control group （n =48） and treatment group （n =48） randomly. The control group was treated with shenkang injection the treatment group was treated with alprostadil combined with shenkang injection. The two groups were treated for 12 days. The levels of 24 h Upro, Uβ2-MG, SCr, BUN, UAER, hs-CRP, TNF-α, IL-6, IL-8 and IL-18 of the two groups before and after treatment were compared. Results： There were no signifieantly differences of the levels of 24h Upro, Uβ2-MG, SCr, BUN, UAER, hs-CRP, TNF-α, IL-6, IL-8 and IL-18 of the two groups before treatment （P^0.05）. The levels of 24h Upro, Uβ2-MG, SCr, BUN and UAER of the two groups after treatment were significantly lower than before treatment （P〈0.05）, and that of experiment were sig- nificantly lower than control group （P〈0.05）. The levels of hs-CRP, TNF-α, IL-6, IL-8 and IL-18 of the two groups after treatment were significantly lower than before treatment （P〈0.05）, and that of experiment were significantly lower than con- trol group （P （0.05）. Conclusions： Alprostadii combined with shenkang injection can significantly reduce urine protein and ser- um inflammatory, protect renal function of patients with chronic nephritis, and it was worthy clinical application.

关 键 词：前列地尔 肾康注射液 慢性肾炎 尿蛋白 肾功能 血清炎性因子 

分 类 号：R692.3[医药卫生—泌尿科学]